SAN FRANCISCO, CA, Kardigan, a heart health company modernizing cardiovascular drug development, launched with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular diseases closer to the cures they deserve.

The company recently closed a $300 million Series A financing led by Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage. Funds from this raise will be used to advance Kardigan's focus on areas of most unmet need in cardiology, starting with disease opportunities and patient segments that are resistant or poorly managed on current therapies, including primary and secondary cardiomyopathies leading to heart failure.